Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2014) 2014
Publication (173) 173
Book Review (27) 27
Magazine Article (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1899) 1899
female (1360) 1360
fluticasone (1193) 1193
androstadienes - administration & dosage (1120) 1120
male (1096) 1096
androstadienes - therapeutic use (896) 896
androstadienes - adverse effects (890) 890
index medicus (852) 852
middle aged (850) 850
adult (831) 831
asthma - drug therapy (686) 686
administration, inhalation (664) 664
aged (596) 596
double-blind method (539) 539
treatment outcome (527) 527
asthma (519) 519
adolescent (443) 443
child (393) 393
respiratory system (391) 391
corticosteroids (378) 378
fluticasone propionate (359) 359
albuterol - analogs & derivatives (341) 341
breast neoplasms - drug therapy (314) 314
allergy (311) 311
bronchodilator agents - administration & dosage (295) 295
anti-inflammatory agents - administration & dosage (294) 294
drug combinations (280) 280
drug therapy (278) 278
oncology (270) 270
androstadienes - pharmacology (260) 260
budesonide (258) 258
immunology (255) 255
anti-asthmatic agents - administration & dosage (248) 248
drug therapy, combination (248) 248
inhaled corticosteroids (243) 243
pharmacology & pharmacy (237) 237
dose-response relationship, drug (232) 232
asthma - physiopathology (224) 224
salmeterol xinafoate (221) 221
albuterol - administration & dosage (217) 217
breast cancer (216) 216
drug administration schedule (215) 215
anti-inflammatory agents - adverse effects (212) 212
bronchodilator agents - therapeutic use (211) 211
care and treatment (207) 207
albuterol - therapeutic use (205) 205
efficacy (204) 204
salmeterol (203) 203
bronchodilator agents - adverse effects (198) 198
aged, 80 and over (195) 195
anti-asthmatic agents - adverse effects (193) 193
anti-inflammatory agents - therapeutic use (192) 192
pulmonary disease, chronic obstructive - drug therapy (190) 190
postmenopausal women (189) 189
anti-asthmatic agents - therapeutic use (188) 188
children (181) 181
glucocorticoids (180) 180
steroids (175) 175
therapy (175) 175
safety (174) 174
animals (166) 166
medicine, general & internal (166) 166
tamoxifen (165) 165
administration, intranasal (159) 159
administration, topical (158) 158
child, preschool (155) 155
forced expiratory volume - drug effects (155) 155
postmenopause (153) 153
time factors (148) 148
albuterol - adverse effects (147) 147
propionate (146) 146
quality of life (146) 146
glucocorticoids - administration & dosage (143) 143
research (142) 142
adrenal cortex hormones - administration & dosage (141) 141
aromatase inhibitors (140) 140
cross-over studies (140) 140
exemestane (140) 140
analysis (138) 138
aromatase inhibitors - therapeutic use (138) 138
fluticasone-salmeterol drug combination (135) 135
randomized controlled trials as topic (133) 133
budesonide - administration & dosage (131) 131
beclomethasone dipropionate (126) 126
double-blind (126) 126
young adult (125) 125
rhinitis, allergic, seasonal - drug therapy (123) 123
aromatase inhibitors - adverse effects (122) 122
androstadienes - pharmacokinetics (121) 121
health aspects (120) 120
letrozole (119) 119
medicine & public health (116) 116
nebulizers and vaporizers (116) 116
quality-of-life (115) 115
breast neoplasms - pathology (114) 114
cancer (114) 114
clinical trials (114) 114
cardiac & cardiovascular systems (113) 113
hydrocortisone - blood (112) 112
risk factors (112) 112
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1917) 1917
Japanese (20) 20
German (17) 17
French (16) 16
Chinese (8) 8
Dutch (7) 7
Swedish (6) 6
Italian (5) 5
Spanish (5) 5
Danish (4) 4
Polish (4) 4
Hungarian (2) 2
Romanian (2) 2
Russian (2) 2
Czech (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Adverse effects of salmeterol in asthma: a neuronal perspective
by Lommatzsch, M and Lindner, Y and Edner, A and Bratke, K and Kuepper, M and Virchow, J C
Thorax, ISSN 0040-6376, 09/2009, Volume 64, Issue 9, pp. 763 - 769
Background:Regular use of inhaled β2-agonists has been associated with a paradoxical loss of asthma control and a deterioration of airway hyper-responsiveness,... 
MILD ASTHMA | SALBUTAMOL | BRONCHIAL HYPERRESPONSIVENESS | POLYMORPHISMS | RESPIRATORY SYSTEM | NEUROTROPHIC FACTOR | MOUSE MODEL | EXACERBATIONS | HUMAN PLATELETS | ALLERGIC AIRWAY INFLAMMATION | BETA-AGONISTS | Leukocytes, Mononuclear - metabolism | Bronchodilator Agents - administration & dosage | Humans | Bronchial Provocation Tests | Male | Albuterol - antagonists & inhibitors | Brain-Derived Neurotrophic Factor - blood | Fluticasone | Adrenergic beta-2 Receptor Agonists | Forced Expiratory Volume | Young Adult | Histamine - metabolism | Bronchial Hyperreactivity - physiopathology | Adrenergic beta-Agonists - administration & dosage | Albuterol - administration & dosage | Adult | Female | Drug Therapy, Combination | Adrenergic beta-Agonists - adverse effects | Bronchial Hyperreactivity - chemically induced | Salmeterol Xinafoate | Asthma - physiopathology | Receptors, Adrenergic, beta-2 - genetics | Albuterol - analogs & derivatives | Asthma - drug therapy | Polymorphism, Genetic | Androstadienes - administration & dosage | Adolescent | Albuterol - adverse effects | Complications and side effects | Care and treatment | Brain-derived neurotrophic factor | Patient outcomes | Salmeterol | Physiological aspects | Dosage and administration | Research | Drug therapy | Asthma | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Aromatase inhibitor adverse effects: Are we sweeping them under the rug?
by Niravath, Polly and Rimawi, Mothaffar F and Osborne, C. Kent
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 33, pp. 3779 - 3780
Quality of Life | Female | Androstadienes - therapeutic use | Aromatase Inhibitors - therapeutic use | Humans | Breast Neoplasms - prevention & control
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?
by Prasad, Vinay and Diener-West, Marie
CMAJ, ISSN 0820-3946, 06/2015, Volume 187, Issue 9, pp. E276 - E278
  Although chemoprevention of breast cancer has been shown to decrease incident cancer, it has not been shown to avert breast cancer deaths. No drug has been... 
WOMEN | MEDICINE, GENERAL & INTERNAL | MEDICATIONS | RISK REDUCTION | EXEMESTANE | TAMOXIFEN | PROSTATE-CANCER | SERVICES TASK-FORCE | PREVENTION TRIAL | GUIDELINE | Risk Assessment | Chemoprevention | Humans | Middle Aged | Breast Neoplasms - etiology | Breast Neoplasms - prevention & control | Antineoplastic Agents - adverse effects | Adult | Breast Neoplasms - mortality | Female | Aged | Tamoxifen - adverse effects | Androstadienes - adverse effects | Prevention | Complications and side effects | Patient outcomes | Breast cancer | Raloxifene | Dosage and administration | Tamoxifen | Women | Disease prevention | Oncology | Chemotherapy | Side effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
by Nannini, Luis Javier and Nannini, Luis Javier and Lasserson, Toby J and Lasserson, Toby J and Poole, Phillippa and Poole, Phillippa
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2012, Volume 2012, Issue 9, p. CD006829
Background Both inhaled steroids (ICS) and long-acting beta(2)-agonists (LABA) are used in the management of chronic obstructive pulmonary disease (COPD). This... 
Adrenal Cortex Hormones [administration & dosage; adverse effects] | COST-EFFECTIVENESS | Adrenergic beta-Agonists [administration & dosage; adverse effects] | CLINICAL-TRIAL | Humans | FLUTICASONE PROPIONATE/SALMETEROL 250/50 | SALMETEROL/FLUTICASONE PROPIONATE | COPD EXACERBATIONS | LUNG-FUNCTION | RANDOMIZED CONTROLLED-TRIAL | Pneumonia [chemically induced] | Randomized Controlled Trials as Topic | SALMETEROL | Bronchodilator Agents [administration & dosage; adverse effects] | Pulmonary Disease, Chronic Obstructive [drug therapy; mortality] | MEDICINE, GENERAL & INTERNAL | METERED-DOSE INHALER | Quality of Life | Adult | Drug Therapy, Combination | 50 MU-G | Drug Combinations | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - mortality | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Fluticasone | Ethanolamines - administration & dosage | Pneumonia - chemically induced | Adrenergic beta-Agonists - administration & dosage | Albuterol - administration & dosage | Bronchodilator Agents - adverse effects | Adrenergic beta-Agonists - adverse effects | Salmeterol Xinafoate | Albuterol - analogs & derivatives | Adrenal Cortex Hormones - adverse effects | Drug Therapy, Combination - methods | Androstadienes - administration & dosage | Budesonide - adverse effects | Budesonide - administration & dosage | Androstadienes - adverse effects | Albuterol - adverse effects | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
by Pagani, Olivia and Regan, Meredith M and Walley, Barbara A and Fleming, Gini F and Colleoni, Marco and Láng, István and Gomez, Henry L and Tondini, Carlo and Burstein, Harold J and Perez, Edith A and Ciruelos, Eva and Stearns, Vered and Bonnefoi, Hervé R and Martino, Silvana and Geyer, Charles E and Pinotti, Graziella and Puglisi, Fabio and Crivellari, Diana and Ruhstaller, Thomas and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Bernhard, Jürg and Luo, Weixiu and Ribi, Karin and Viale, Giuseppe and Coates, Alan S and Gelber, Richard D and Goldhirsch, Aron and Francis, Prudence A and TEXT SOFT Investigators Int Breast and International Breast Cancer Study Group and TEXT and SOFT Investigators
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 107 - 118
Aromatase inhibitors are somewhat more effective than tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer. This benefit was extended... 
TRIAL | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | TAMOXIFEN | SEQUENCE | LETROZOLE | ENDOCRINE THERAPY | FOLLOW-UP | POSTMENOPAUSAL WOMEN | AMERICAN-SOCIETY | Estradiol - blood | Breast Neoplasms - surgery | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Osteoporosis - chemically induced | Premenopause | Kaplan-Meier Estimate | Triptorelin Pamoate - adverse effects | Triptorelin Pamoate - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Quality of Life | Androstadienes - therapeutic use | Tamoxifen - adverse effects | Androstadienes - adverse effects | Care and treatment | Breast cancer | Research | Ovariectomy | Invasiveness | Radiation | Clinical trials | Data processing | Pituitary (anterior) | Gonadotropins | Tamoxifen | Survival | Patients | Clinical outcomes | Post-menopause | Chemotherapy | Aromatase
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
by Nannini, Luis Javier and Nannini, Luis Javier and Poole, Phillippa and Poole, Phillippa and Milan, Stephen J and Milan, Stephen J and Kesterton, Annabel and Kesterton, Annabel
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 8, Issue 12, p. CD006826
Background Both long-acting beta(2)-agonists and inhaled corticosteroids have been recommended in guidelines for the treatment of chronic obstructive pulmonary... 
Adrenal Cortex Hormones [administration & dosage; adverse effects] | COST-EFFECTIVENESS | Adrenergic beta-Agonists [administration & dosage; adverse effects] | EFFICACY | Humans | SALMETEROL/FLUTICASONE PROPIONATE | Steroids [administration & dosage; adverse effects] | Pneumonia [chemically induced] | Randomized Controlled Trials as Topic | SALMETEROL | Bronchodilator Agents [administration & dosage; adverse effects] | Pulmonary Disease, Chronic Obstructive [drug therapy; mortality] | MEDICINE, GENERAL & INTERNAL | FLUTICASONE PROPIONATE | COMBINED MOMETASONE FUROATE | FIXED-DOSE COMBINATION | Drug Therapy, Combination | CHINESE PATIENTS | Drug Combinations | Nebulizers and Vaporizers | HEALTH-STATUS | COPD | Pulmonary Disease, Chronic Obstructive - mortality | Steroids - administration & dosage | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Ethanolamines - administration & dosage | Drug Therapy, Combination - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Pneumonia - chemically induced | Albuterol - administration & dosage | Bronchodilator Agents - adverse effects | Steroids - adverse effects | Albuterol - analogs & derivatives | Adrenal Cortex Hormones - adverse effects | Drug Therapy, Combination - methods | Androstadienes - administration & dosage | Budesonide - adverse effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Budesonide - administration & dosage | Fluticasone-Salmeterol Drug Combination | Androstadienes - adverse effects | Albuterol - adverse effects | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
by Ryan, Charles J and Smith, Matthew R and de Bono, Johann S and Molina, Arturo and Logothetis, Christopher J and de Souza, Paul and Fizazi, Karim and Mainwaring, Paul and Piulats, Josep M and Ng, Siobhan and Carles, Joan and Mulders, Peter F.A and Basch, Ethan and Small, Eric J and Saad, Fred and Schrijvers, Dirk and Van Poppel, Hendrik and Mukherjee, Som D and Suttmann, Henrik and Gerritsen, Winald R and Flaig, Thomas W and George, Daniel J and Yu, Evan Y and Efstathiou, Eleni and Pantuck, Allan and Winquist, Eric and Higano, Celestia S and Taplin, Mary-Ellen and Park, Youn and Kheoh, Thian and Griffin, Thomas and Scher, Howard I and Rathkopf, Dana E and COU-AA-302 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 2, pp. 138 - 148
Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant... 
HUMAN CYTOCHROME P450(17-ALPHA) | CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | PREDNISONE | MITOXANTRONE | INHIBITION | END-POINTS | CYP17 | ACETATE | DOCETAXEL | HORMONAL-THERAPY | Prednisone - adverse effects | Double-Blind Method | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms - mortality | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Neoplasm Metastasis | Prostatic Neoplasms - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Survival Analysis | Androstadienes - therapeutic use | Androstadienes - adverse effects | Prednisone - therapeutic use | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Chemotherapy | Usage | Care and treatment | Patient outcomes | Product/Service Evaluations | Drug therapy | Prostate cancer | Cancer | Clinical trials | Cancer therapies | Regulatory approval | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
by Francis, Prudence A and Regan, Meredith M and Fleming, Gini F and Láng, István and Ciruelos, Eva and Bellet, Meritxell and Bonnefoi, Hervé R and Climent, Miguel A and Da Prada, Gian Antonio and Burstein, Harold J and Martino, Silvana and Davidson, Nancy E and Geyer, Charles E and Walley, Barbara A and Coleman, Robert and Kerbrat, Pierre and Buchholz, Stefan and Ingle, James N and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Colleoni, Marco and Viale, Giuseppe and Coates, Alan S and Goldhirsch, Aron and Gelber, Richard D and Int Breast Canc Study Grp and SOFT Investigators and International Breast Cancer Study Group
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
This trial did not support routine use of ovarian suppression in premenopausal breast cancer. Nevertheless, there may be some benefit from ovarian suppression... 
AMENORRHEA | MEDICINE, GENERAL & INTERNAL | THERAPY | YOUNG-WOMEN | CHEMOTHERAPY | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogen | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
by Kew, Kayleigh M and Kew, Kayleigh M and Seniukovich, Alieksei and Seniukovich, Alieksei
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 3, p. CD010115
Background Inhaled corticosteroids (ICS) are anti-inflammatory drugs that have proven benefits for people with worsening symptoms of chronic obstructive... 
MEDICINE, GENERAL & INTERNAL | EUROPEAN RESPIRATORY SOCIETY | METERED-DOSE INHALER | FLUTICASONE PROPIONATE/SALMETEROL 250/50 | DOUBLE-BLIND | COPD EXACERBATIONS | LUNG-FUNCTION | BRONCHOALVEOLAR LAVAGE CELLS | 50 MU-G | LONG-TERM TREATMENT | HEALTH-STATUS | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Administration, Inhalation | Male | Fluticasone | Randomized Controlled Trials as Topic | Drug Therapy, Combination - methods | Androstadienes - administration & dosage | Anti-Inflammatory Agents - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Pneumonia - chemically induced | Budesonide - adverse effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Anti-Inflammatory Agents - administration & dosage | Female | Budesonide - administration & dosage | Bronchodilator Agents - adverse effects | Androstadienes - adverse effects | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights